Traws Pharma (TRAW) Expected to Announce Earnings on Monday

Traws Pharma (NASDAQ:TRAW) is expected to be announcing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($1.91) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 12:30 PM ET.

Traws Pharma Stock Down 1.8%

NASDAQ:TRAW opened at $2.14 on Monday. Traws Pharma has a twelve month low of $0.97 and a twelve month high of $3.27. The stock’s 50-day simple moving average is $1.94 and its 200 day simple moving average is $2.03. The firm has a market capitalization of $17.10 million, a PE ratio of 0.02 and a beta of 1.69.

Analysts Set New Price Targets

A number of research analysts have recently commented on TRAW shares. LADENBURG THALM/SH SH raised shares of Traws Pharma to a “strong-buy” rating in a report on Friday, January 30th. Wall Street Zen cut shares of Traws Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Zacks Research raised shares of Traws Pharma to a “hold” rating in a research note on Thursday, December 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Traws Pharma in a research report on Monday, December 22nd. Finally, HC Wainwright began coverage on shares of Traws Pharma in a research note on Wednesday, December 3rd. They set a “buy” rating and a $8.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $8.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. State Street Corp acquired a new stake in Traws Pharma during the 4th quarter worth approximately $29,000. Two Sigma Investments LP increased its position in Traws Pharma by 37.1% in the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after acquiring an additional 5,955 shares during the period. XTX Topco Ltd raised its stake in shares of Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after acquiring an additional 31,502 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Traws Pharma by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after purchasing an additional 18,213 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Traws Pharma during the fourth quarter worth $175,000. Institutional investors own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.